EZH2 inhibitors: a patent review (2014-2016). - Wikidata - wikimedia - TriplyDB

EZH2 inhibitors: a patent review (2014-2016).

EZH2 inhibitors: a patent review (2014-2016).

http://www.wikidata.org/entity/Q38844652

about

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.Histone methylation changes are required for life cycle progression in the human parasite Schistosoma mansoni.

P2860

Q49874405-30E5445E-20FF-4F42-A0B9-7AFC3F5882A2 Q55176668-98063BA6-71FE-47E9-8C67-032EF8EF1A5D

P2860

EZH2 inhibitors: a patent review (2014-2016).

http://www.wikidata.org/entity/Q38844652

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

EZH2 inhibitors: a patent review (2014-2016).

@en

type

label

EZH2 inhibitors: a patent review (2014-2016).

@en

prefLabel

EZH2 inhibitors: a patent review (2014-2016).

@en

P1433

Q38844652-14551896-9829-4132-99BF-CDA0EC39E5A6

P1476

Q38844652-E44BB656-A761-4B6C-9C8A-ECB13C45ABFB

P2093

Q38844652-E2A32159-DEAD-4A77-84F9-204F40F17EBF

P2860

Q38844652-05BB5156-C1A0-4CF2-9085-857B44B96BC2

Q38844652-06AF03E3-C2EB-44E0-9334-15C40E5DDFFA

Q38844652-08BAE202-A30E-4ADF-B82F-B32FB2D334B1

Q38844652-0C112946-99AC-4FB0-9CB1-9BAEFAEF1803

Q38844652-12DAF6CC-B33B-42E2-85F3-F64FEDDC20E4

Q38844652-22980264-75A2-4761-AC21-81C0C0606336

Q38844652-2320BBC8-3C77-4E8F-8AAE-B9978243E13B

Q38844652-2DBF34F4-8882-4FD0-93C3-4ED4D0817070

Q38844652-3131CCAB-FFD5-4574-B4D5-4AAE9EACD619

Q38844652-3652508D-8A30-45EE-AA0A-D0365CA5A73A

P304

Q38844652-4471F366-6595-44D3-B071-817223088684

P31

Q38844652-1D530B69-CBB9-41FF-8494-54ED140320EB

P356

Q38844652-013464C3-087A-4C4A-A402-7A2296643829

P407

Q38844652-7859CBE6-12D6-4304-81A5-5EC4572693E2

P433

Q38844652-8026009F-C166-4C70-B371-DCA8EF3D9A6D

P478

Q38844652-B6A2B6E7-C06A-44AA-B67C-C801C567B79D

P50

Q38844652-496430E6-0AB3-46B7-B05A-95F2336182B4

Q38844652-62F04BA9-EDA7-4382-9708-C8BEDB1B97C8

Q38844652-CF6BAEC8-6774-418E-B4AD-92DB7D5D06A7

Q38844652-F7BF0CB8-7906-46E8-BB39-565E9BC342C8

P577

Q38844652-ABE34552-FA59-4F49-B19A-AC07123254D2

P698

Q38844652-AD629E71-CD24-4B84-870A-95D7F006FBD2

P356

13543776.2017.1316976

P1433

Expert Opinion on Therapeutic Patents

P1476

EZH2 inhibitors: a patent review (2014-2016)

@en

P2093

Sergio Valente

http://www.w3.org/2001/XMLSchema#string

P2860

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases

Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy

Targeting EZH2 in cancer

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

Epigenetic polypharmacology: from combination therapy to multitargeted drugs

The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

P304

797-813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13543776.2017.1316976

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Clemens Zwergel

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28394193

http://www.w3.org/2001/XMLSchema#string